Inflammatory and Thrombotic Biomarkers in HIV Patients Starting Antiretroviral Therapy
Author Information
Author(s): Sergio Padilla, Mar Masiá, Natalia García, Inmaculada Jarrin, Consuelo Tormo, Félix Gutiérrez
Primary Institution: Hospital General Universitario de Elche, University Miguel Hernández
Hypothesis
What are the early changes in inflammatory and pro-thrombotic biomarkers in patients starting antiretroviral therapy with abacavir or tenofovir?
Conclusion
Changes in biomarkers of inflammation, coagulation, and endothelial function are similar in patients starting ART with abacavir or tenofovir.
Supporting Evidence
- The endothelial biomarker sVCAM-1 declined significantly in both treatment groups.
- hsCRP tended to increase soon after starting therapy with abacavir.
- IL-6 significantly increased only at week 24 from baseline in patients on abacavir.
- PAI-1 plasma levels increased significantly in patients on tenofovir at multiple time points.
Takeaway
This study looked at how certain blood markers change when people start taking HIV medicine. It found that both medicines affect these markers in similar ways.
Methodology
Patients were evaluated at baseline and at weeks 4, 12, 24, and 48, with blood samples taken to measure various biomarkers.
Potential Biases
Non-randomized assignment of therapy groups may introduce bias.
Limitations
The study had a small sample size and was not randomized, which may limit the findings.
Participant Demographics
Patients were mostly Caucasian, with a median age of 35 years for abacavir and 40 years for tenofovir; 64% were ART-naïve.
Statistical Information
P-Value
p < 0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website